Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Бронхиальная астма и малые дыхательные пути. Роль экстрамелкодисперсной фиксированной комбинации в противовоспалительной терапии
Бронхиальная астма и малые дыхательные пути. Роль экстрамелкодисперсной фиксированной комбинации в противовоспалительной терапии
Н.П.Княжеская, А.В.Черняк. Бронхиальная астма и малые дыхательные пути. Роль экстрамелкодисперсной фиксированной комбинации в противовоспалительной терапии. Consilium Medicum. Пульмонология (Прил.). 2011; 1: 22-27.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Acerbi D, Brambilla G, Kottakis I. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology. Pulm Pharmacol Ther 2007; 20: 290–303.
2. Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994; 93: 967–76.
3. Anderson PJ. Delivery options and devices for aerosolized therapeutics. Chest 2001; 120 (Suppl. 3): 89S–93S.
4. Barnes PJ. Clinical outcome of adding long-acting b-agonists to inhaled corticosteroids. Respir Med 2001; 95 (Suppl. B): S12–6.
5. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: 868–75.
6. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting b2-agonists and corticosteroids. Eur Respir J 2002; 19: 182–91.
7. Bateman ED, Boushey HA, Bousquet J et al. Pedersen SE for the GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med 2004; 170: 836–44.
8. Becker A, Lemiиre C et al. Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003. CMAJ 2005; 173 (Suppl. 6): S3–11.
9. Bonnet-Gonod F, Kottakis I, Hofman T et al. Beclomethasone dipropionate/ formoterol in a single inhaler improves lung function and clinically meaningful outcomes in moderate to severe asthma (abstract). Eur Respir J 2006; 28 (Suppl. 50): P1230.
10. Boulet LP, Cartier A, Ernst P et al. Safety and efficacy of HFA-134a beclomethasone dipropionate extrafine aerosol over six months. Can Respir J 2004; 11: 123–30.
11. Bousquet J, Dell'Anna C. Modulite technology in the development of formoterol HFApMDI: clinical evidence and future opportunities. Expert Rev Resp Med 2008; 2 (1): 27–36.
12. Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Resp J 1997; 10: 292–300.
13. Contoli M, Bousquet J, Fabbri LM et al. The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy 2009. DOI: 10.1111/j.1398-9995.2009.02242.x
14. Dhillon S, Keating GM. Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler. Drugs 2006; 66: 1475–83.
15. Global Initiative for Asthma. Workshop Report, 2006. http://www.ginasthma.com/download.asp?intId=217
16. Hamid Q. Peripheral inflammation is more important than central inflammation. Respir Med 1997; 91: 11–2.
17. Huchon G et al. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 2008. Doi:10.1016/j.rmed. 2008.09.002
18. Kuyper LM, Pare PD, Hogg JC et al. Characterisation of airways plugging in fatal asthma Am J Med 2003; 115: 6–11.
19. Mak JCW, Nishikawa M, Shirasaki H et al. Protective effects of a glucocorticoid on downregulation of pulmonary b2-adrenergic receptors in vivo. J Clin Invest 1995; 96: 99–106.
20. Mariotti F, Poli G, Acerbi D et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic and COPD patients. Eur Res Congr 2008. Abstract book: Poster P649.
21. Minshall EM, Hogg JC, Hamid QA. Cytokine mRNA expression in asthma is not restricted to the large airways. J Allergy Clin Immunol 1998; 101: 386–90.
22. O’Connor BJ et al. ERS 2009.
23. Papi A, Paggiaro PL, Nicolini G et al. Bеclomethasone/formoterol versus bude-sonide/formoterol combination therapy in asthma. Eur Respir J 2007; 29: 682–9.
24. Papi A, Paggiaro P, Nicolini G et al. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combinationin moderate to severe asthma. Allergy 2007; 62: 1182–8.
25. Scichilone N, Contino A, Figlioli G et al. Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment options. Published online, 2010 February 4.
26. Vos WV, Devolder AD, Debacke LD et al. Long-term effects of combined extrafine beclomethasone (BECL) and formoterol (FORM) treatment in asthma patients. Eur Respir J 2009; 34: S53.
2. Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994; 93: 967–76.
3. Anderson PJ. Delivery options and devices for aerosolized therapeutics. Chest 2001; 120 (Suppl. 3): 89S–93S.
4. Barnes PJ. Clinical outcome of adding long-acting b-agonists to inhaled corticosteroids. Respir Med 2001; 95 (Suppl. B): S12–6.
5. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: 868–75.
6. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting b2-agonists and corticosteroids. Eur Respir J 2002; 19: 182–91.
7. Bateman ED, Boushey HA, Bousquet J et al. Pedersen SE for the GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med 2004; 170: 836–44.
8. Becker A, Lemiиre C et al. Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003. CMAJ 2005; 173 (Suppl. 6): S3–11.
9. Bonnet-Gonod F, Kottakis I, Hofman T et al. Beclomethasone dipropionate/ formoterol in a single inhaler improves lung function and clinically meaningful outcomes in moderate to severe asthma (abstract). Eur Respir J 2006; 28 (Suppl. 50): P1230.
10. Boulet LP, Cartier A, Ernst P et al. Safety and efficacy of HFA-134a beclomethasone dipropionate extrafine aerosol over six months. Can Respir J 2004; 11: 123–30.
11. Bousquet J, Dell'Anna C. Modulite technology in the development of formoterol HFApMDI: clinical evidence and future opportunities. Expert Rev Resp Med 2008; 2 (1): 27–36.
12. Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Resp J 1997; 10: 292–300.
13. Contoli M, Bousquet J, Fabbri LM et al. The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy 2009. DOI: 10.1111/j.1398-9995.2009.02242.x
14. Dhillon S, Keating GM. Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler. Drugs 2006; 66: 1475–83.
15. Global Initiative for Asthma. Workshop Report, 2006. http://www.ginasthma.com/download.asp?intId=217
16. Hamid Q. Peripheral inflammation is more important than central inflammation. Respir Med 1997; 91: 11–2.
17. Huchon G et al. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 2008. Doi:10.1016/j.rmed. 2008.09.002
18. Kuyper LM, Pare PD, Hogg JC et al. Characterisation of airways plugging in fatal asthma Am J Med 2003; 115: 6–11.
19. Mak JCW, Nishikawa M, Shirasaki H et al. Protective effects of a glucocorticoid on downregulation of pulmonary b2-adrenergic receptors in vivo. J Clin Invest 1995; 96: 99–106.
20. Mariotti F, Poli G, Acerbi D et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic and COPD patients. Eur Res Congr 2008. Abstract book: Poster P649.
21. Minshall EM, Hogg JC, Hamid QA. Cytokine mRNA expression in asthma is not restricted to the large airways. J Allergy Clin Immunol 1998; 101: 386–90.
22. O’Connor BJ et al. ERS 2009.
23. Papi A, Paggiaro PL, Nicolini G et al. Bеclomethasone/formoterol versus bude-sonide/formoterol combination therapy in asthma. Eur Respir J 2007; 29: 682–9.
24. Papi A, Paggiaro P, Nicolini G et al. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combinationin moderate to severe asthma. Allergy 2007; 62: 1182–8.
25. Scichilone N, Contino A, Figlioli G et al. Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment options. Published online, 2010 February 4.
26. Vos WV, Devolder AD, Debacke LD et al. Long-term effects of combined extrafine beclomethasone (BECL) and formoterol (FORM) treatment in asthma patients. Eur Respir J 2009; 34: S53.
Авторы
Н.П.Княжеская1, А.В.Черняк2
1 Кафедра пульмонологии ФУВ ГБОУ ВПО РНИМУ им. Н.И.Пирогова;
2 НИИ пульмонологии ФМБА России
1 Кафедра пульмонологии ФУВ ГБОУ ВПО РНИМУ им. Н.И.Пирогова;
2 НИИ пульмонологии ФМБА России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.